| Assay ID | Title | Year | Journal | Article |
|---|
| AID1540783 | Inhibition of rhVEGF-A-induced of VEGFR2 phosphorylation at Tyr1175 residue in HUVEC at 0.1 uM incubated for 2 hrs by Western blot analysis | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1540766 | Inhibition of TEL-fused FLT3 (unknown origin) expressed in mouse BA/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell-titer-Glo assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779542 | Anticancer activity against human MDA-MB-231 cells assessed as cell viability incubated for 48 hrs by MTT assay | | | |
| AID1540764 | Inhibition of human FLT3 using EAIYAAPFAKKK substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779536 | Antimetastatic activity against human MDA-MB-231 cells injected into vein of BALB/c mouse lung metastatic model assessed as less lung metastatic nodules at 25 mg/kg, po once a day measured on day 21 | | | |
| AID1779613 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as creatinine level in blood at 300 mg/kg, po | | | |
| AID1779533 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as LDH level in blood at 300 mg/kg, po | | | |
| AID1779534 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as AST level in blood at 300 mg/kg, po | | | |
| AID1779619 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as change in kidney at 300 mg/kg, po by hematoxylin and eosin staining based analysis | | | |
| AID1540791 | Anti-angiogenesis activity in truncated-FOSB transfected HUVEC cells model of pseudomyogenic-hemangioendothelioma assessed as inhibition of tube formation up to 5 uM | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1540767 | Growth inhibition of mouse BA/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell-titer-Glo assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779556 | Selectivity ratio of IC50 for human VEGFR2 to IC50 for human VEGFR3 | | | |
| AID1779535 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as ALT level in blood at 300 mg/kg, po | | | |
| AID1540763 | Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779616 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as change in liver at 300 mg/kg, po by hematoxylin and eosin staining based analysis | | | |
| AID1540786 | Anti-angiogenesis activity in HUVEC assessed as inhibition of VEGF-A-induced tube formation at 0.1 uM incubated for 6 hrs by tube formation assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1540761 | Inhibition of TEL-fused VEGFR2 (unknown origin) expressed in mouse BA/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell-titer-Glo assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779611 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as effect on body weight at 50 mg/kg, po | | | |
| AID1540787 | Anti-lymphangiogenic activity in C57BL/6 mouse assessed as suppression of suture-induced corneal lymphangiogenesis at 200 nM administered topically every 12 hrs for 7 days by immunohistochemical analysis | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1540784 | Inhibition of rhVEGF-A-induced of VEGFR2 phosphorylation at Tyr1175 residue in HUVEC at 0.1 uM by ELISA | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779561 | Inhibition of cell migration in VEGF-C-induced human dermal lymphatic endothelial cells assessed as cell migration at 100 nM incubated for 24 hrs by inverted microscopy based by scratch wound healing assay | | | |
| AID1779609 | Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c mouse assessed as reduction in tumor volume at 25 mg/kg, po | | | |
| AID1540780 | Anti-lymphangiogenic activity in HDLEC assessed as reduction in growth factor cocktail-induced lymphatic sprouting at 10 uM incubated for 4 days by Hoechst 33342 and phalloidin staining based microfluidic platform assay relative to control | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1540789 | Toxicity in C57BL/6 mouse assessed as induction of clinically detectable corneal-epitheliopathy at 200 nM administered topically every 12 hrs for 7 days by immunohistochemical analysis | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779562 | Antimigratory activity against VEGF-C-induced human dermal lymphatic endothelial cells assessed as cell migration at 100 nM incubated for 12 hrs by inverted microscopy based by transwell assay | | | |
| AID1540765 | Inhibition of human VEGFR3 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779559 | Antiproliferative activity against VEGF-D-induced human dermal lymphatic endothelial cells assessed as cell viability incubated for 48 hrs by CCK-8 assay | | | |
| AID1779620 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as change in liver at 25 mg/kg, po by hematoxylin and eosin staining based analysis | | | |
| AID1779558 | Antiproliferative activity against VEGF-C-induced human dermal lymphatic endothelial cells assessed as cell viability incubated for 48 hrs by CCK-8 assay | | | |
| AID1779560 | Anti-lymphangiogenic activity against human dermal lymphatic endothelial cells assessed as inhibition of VEGF-C-mediated tube formation at 100 nM incubated for 12 hrs by inverted microscopy | | | |
| AID1779543 | Anticancer activity against human MDA-MB-436 cells assessed as cell viability incubated for 48 hrs by MTT assay | | | |
| AID1779541 | Inhibition of VEGFR3 (unknown origin) at 1 uM incubated for 1 hr by ELISA relative to control | | | |
| AID1779615 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as change in heart at 300 mg/kg, po by hematoxylin and eosin staining based analysis | | | |
| AID1540785 | Anti-angiogenesis activity in HUVEC assessed as inhibition of VEGF-A-induced cell migration at 0.1 uM incubated for 12 hrs by wound healing assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779614 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as uric acid level in blood at 300 mg/kg, po | | | |
| AID1779557 | Selectivity ratio of IC50 for human VEGFR1 to IC50 for human VEGFR3 | | | |
| AID1540762 | Inhibition of TEL-fused VEGFR3 (unknown origin) expressed in mouse BA/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell-titer-Glo assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. |
| AID1779617 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as change in spleen at 300 mg/kg, po by hematoxylin and eosin staining based analysis | | | |
| AID1779618 | Toxicity in BALB/c mouse xenografted with MDA-MB-231 cells assessed as change in lung at 300 mg/kg, po by hematoxylin and eosin staining based analysis | | | |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |